Species-Specific Immunity Induced by Infection with *Entamoeba histolytica* and *Entamoeba moshkovskii* in Mice

Chikako Shimokawa¹, Richard Culleton², Takashi Imai³, Kazutomo Suzue³, Makoto Hirai³, Tomoyo Taniguchi³, Seiki Kobayashi⁴, Hajime Hisaeda³, Shinjiro Hamano¹,5*

¹ Department of Parasitology, Nagasaki University, Nagasaki, Japan, ² Malaria Unit, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan, ³ Department of Parasitology, Graduate School of Medicine, Gunma University, Gunma, Japan, ⁴ Department of Tropical Medicine and Parasitology, Keio University School of Medicine, Shinjuku, Tokyo, Japan, ⁵ Global COE Program, Nagasaki University, Nagasaki, Japan

Abstract

*Entamoeba histolytica*, the parasitic amoeba responsible for amoebiasis, causes approximately 100,000 deaths every year. There is currently no vaccine against this parasite. We have previously shown that intracecal inoculation of *E. histolytica* trophozoites leads to chronic and non-healing cecitis in mice. *Entamoeba moshkovskii*, a closely related amoeba, also causes diarrhea and other intestinal disorders in this model. Here, we investigated the effect of infection followed by drug-cure of these species on the induction of immunity against homologous or heterologous species challenge. Mice were infected with *E. histolytica* or *E. moshkovskii* and treated with metronidazole 14 days later. Re-challenge with *E. histolytica* or *E. moshkovskii* was conducted seven or 28 days following confirmation of the clearance of amoebae, and the degree of protection compared to non-exposed control mice was evaluated. We show that primary infection with these amoebae induces a species-specific immune response which protects against challenge with the homologous, but not a heterologous species. These findings pave the way, therefore, for the identification of novel amoebae antigens that may become the targets of vaccines and provide a useful platform to investigate host protective immunity to *Entamoeba* infections.

Introduction

Amoebiasis, an infectious disease caused by the parasitic protozoan *Entamoeba histolytica* is responsible for over 50 million cases in tropical regions and nearly 100,000 deaths worldwide each year. Infection is initiated through the ingestion of cysts in contaminated food or water. *E. histolytica* primarily infects the intestine, and may cause a wide range of symptoms from mild diarrhea to serious dysentery. If untreated, the parasite can cause life-threatening hemorrhagic colitis and/or extra-intestinal abscesses [1-5].

*E. histolytica* trophozoites are able to colonize the human intestine by adhering to colonic mucins and subsequently to epithelial cells via cell surface lectin [6]. This lectin is important for colonic colonization by *E. histolytica*. A colonization-blocking vaccine targeting this parasite lectin could prevent trophozoite adherence and thus provide protection against subsequent invasive disease [7]. Furthermore, recently, it has also been reported that there is a correlation between the presence of anti-lectin fecal immunoglobulin A (IgA) antibodies and protection from parasitic colonization in humans and mice [7-9]. These reports suggest that amoebiasis can be controlled by acquired immunity.

*Entamoeba moshkovskii* is closely related to *Entamoeba dispar* and *E. histolytica* and is microscopically indistinguishable from them in its cyst and trophozoite forms [10]. Recently, we reported that *E. moshkovskii* causes diarrhea, colitis and weight loss in mice, and that in...
Bangladeshi children, acquisition of *E. moshkovskii* infection was associated with diarrhea [11].

Here, using *E. histolytica* and *E. moshkovskii* infections in mice, we evaluate whether the immunity against re-infection that occurs following a primary infection is species-specific. We find that, following a primary infection with either *E. histolytica* or *E. moshkovskii*, mice are protected from re-challenge with a homologous species, but remained susceptible to a heterologous species. These results show, for the first time, that the immunity acquired during primary infection with *Entamoeba* spp. confers species-specific protective immunity.

**Materials and Methods**

**Mice**

Male CBA/J mice were purchased from Jackson Laboratories. Animals were maintained under specific pathogen free conditions at theAnimal Research Center for Tropical Infectious Diseases, Nagasaki University, and were challenged when they were 5-8 weeks old. All experiments that involved mice were reviewed and approved by the Committee for Ethics on Animal Experiments of the Graduate School of Medicine, Nagasaki University, and the Law (No. 105) and Notification (No. 6) of the Japanese Government pertaining to the use of experimental animals.

**Parasite Culture and Infection**

Trophozoites of *E. histolytica*, originally laboratory strain HM1:IMSS (American Type Culture Collection, Manassas, VA), were from Prof. Eric Houpt, University of Virginia, and were serially passaged in vivo through the ceca of mice [12]. Trophozoites of the *E. moshkovskii* Laredo strain, were a gift from Dr. Seiki Kobayashi, Keio University, School of Medicine (originally from the late professor Louis S. Diamond, NIH, Bethesda, Maryland). Cecal contents were cultured at 37°C and 25°C, respectively, in BIS-33 medium supplemented with heat-inactivated 10% adult bovine serum, 25U/ml penicillin and 25 mg/ml streptomycin [13]. Trophozoites in the logarithmic growth phase were used in the experiments.

**Intracecal inoculation of Entamoeba spp**

Trophozoites of *E. histolytica* HM1:IMSS and *E. moshkovskii* Laredo strain were collected after incubating the tubes on ice for 5-10 minutes. Then, the number of trophozoites was counted. We anesthetized mice with Domitor (medetomidine hydrochloride: 0.1mg/kg) and Dormicum (midazolam: 0.1 mg/kg), shaved their abdomens to incise the skin, exteriorized each cecum from the peritoneum, and injected 150μl of 1×10⁶ trophozoites into the apical sites of cecum. Then, the cecum was blotted and the peritoneum and the skin were sutured. Mice were kept on warming blankets at 37°C throughout surgery. Survival rates were ≥90% in all mice.

**Detection of each Entamoeba spp. by PCR using DNA extracted from stool of mice**

For isolation of *Entamoeba* DNA from mouse stools, QI Amp DNA Stool Kits (QIAGEN, Valencia CA) were used according to manufacturer’s instructions. The primer sequences used for PCR are as previously described [14].

**Administration of metronidazole**

For in vivo studies, stock solutions of metronidazole (Sigma Aldrich, St. Louis, MO) were prepared in 100% dimethyl sulfoxide at a concentration of 10 mg/mL and stored at 4°C. The stock solution was diluted 32 times with distilled water to 0.3125 mg/mL, in which the concentration of DMSO was 3.125%. Mice were treated orally with metronidazole at a dose of 12.5mg/kg of body weight. To cure primary infections with *E. histolytica* or with *E. moshkovskii*, all of mice challenged with *E. histolytica* or with *E. moshkovskii* were treated with 1 mL of metronidazole orally (0.3125 mg/mL) using gastric intubation on day 14 post-infection. Naïve mice were also administered with metronidazole and used as control.

**Statistical analysis**

Differences between groups were analyzed for statistical significance with unpaired Student’s *t*-test and χ² test. All of these were performed using Excel software. Probabilities below 0.05 were considered statistically significant.

**Results**

**E. moshkovskii** infections were resolved earlier than *E. histolytica* infections

We have previously demonstrated that C3H/HeN, C3H/HeJ and CBA/J mice allow the establishment of *E. histolytica* and *E. moshkovskii* infections, while many strains of mice including C57BL/6 and BALB/c mice do not, indicating that susceptibility to *E. histolytica* and *E. moshkovskii* infection is dependent on the genetic background of the host [11,12,15-17]. Trophozoites of *E. histolytica* and *E. moshkovskii* were intracceclally inoculated into CBA/J mice. As expected, both *E. histolytica* and *E. moshkovskii* succeded in infecting CBA/J mice after challenge (Figure 1). *E. histolytica* infected the ceca in approximately 80% of CBA/J mice (16 of 20) as confirmed by both culture and PCR of intracecal contents two days after challenge. In contrast, *E. moshkovskii* infected the ceca of CBA/J mice in approximately 65% of mice (13 of 20) at the same point. At day 14 post-challenge, the infection rate of *E. histolytica* was approximately 60% (12 of 20 mice positive), though that of *E. moshkovskii* was approximately 5% of mice (1 of 20). At 21 days post-challenge, the infection rate of *E. histolytica* was approximately 58% (11 of 19) and that of *E. moshkovskii* was 0%.

**Metronidazole Sensitivity in E. moshkovskii**

So as to treat mice infected with *E. histolytica* and *E. moshkovskii*, the effect of metronidazole on the growth and survival of *E. histolytica* and *E. moshkovskii* trophozoites was evaluated in vitro. The number of viable cells in glass tubes
was counted after incubation of *E. histolytica* and *E. moshkovskii* with various concentrations of metronidazole for 48h. The numbers of *E. histolytica* and *E. moshkovskii* treated with metronidazole decreased significantly in a dose dependent manner (Figure 2).

**Amoebic infection induced species-specific protective immunity**

In order to examine whether protection against re-infection can be induced by primary infection, the mice that allowed the establishment of the primary infection with *E. histolytica* or *E.

---

Figure 1. Entamoeba moshkovskii infections were resolved earlier than *Entamoeba histolytica* infections. CBA/J mice were intracecaally infected with $1 \times 10^6$ trophozoites of *E. histolytica* and *E. moshkovskii*. Infection rate was monitored by detecting amoebae in caecal content and by amplifying the amoeba gene from faecal DNA on days 2, 7, 14, and 21. Infection rate of mice with *E. histolytica* and *E. moshkovskii* was shown as open and closed columns, respectively. Values show the representative result out of 3 individual experiments. Asterisks indicate statistical significance with $p < 0.05$ between mice infected with *E. histolytica* and *E. moshkovskii* by $\chi^2$ test.

doi: 10.1371/journal.pone.0082025.g001

Figure 2. The effect of metronidazole on the growth and survival of *Entamoeba histolytica* and *Entamoeba moshkovskii* trophozoites was evaluated in vitro. *E. histolytica* and *E. moshkovskii* were incubated with various concentrations of metronidazole for 48h. Then, the number of viable cells was counted and the proportion of it versus initial number was shown as open and closed columns, respectively.

doi: 10.1371/journal.pone.0082025.g002
moshkovskii were treated with metronidazole on day 14 and used for the secondary challenge. The clearance of amoeba was confirmed seven days after treatment by PCR. Mice were kept without any intervention for an additional week, and then re-challenged with 1 × 10⁶ trophozoites of *E. histolytica* (A, B) or *E. moshkovskii* (C, D) at 14 days after treatment. The number of mice used was as follows: for naïve→*E. histolytica*, N=16; for *E. histolytica*→*E. histolytica*, N=20; for *E. moshkovskii*→*E. histolytica*, N=20 (A, B); for naïve→*E. moshkovskii*, N=20; for *E. histolytica*→*E. moshkovskii*, N=20; for *E. moshkovskii*→*E. moshkovskii*, N=20 (C, D). Asterisks indicate statistical significance with p < 0.05 by χ² test between mice infected with *E. histolytica* and *E. moshkovskii* in the primary infection.

doi: 10.1371/journal.pone.0082025.g003

**Figure 3.** Amoebic infection induced species-specific protective immunity. Mice were infected with 1 × 10⁶ trophozoites of *Entamoeba histolytica* (open triangle) or *Entamoeba moshkovskii* (open circle) and treated with metronidazole (Mz) on day 14 following induction of the primary infection. The clearance of amoeba was confirmed seven days after treatment by PCR. Mice were kept without any intervention for an additional week, and then re-challenged with 1 × 10⁶ trophozoites of *E. histolytica* (A, B) or *E. moshkovskii* (C, D) at 14 days after treatment. The number of mice used was as follows: for naïve→*E. histolytica*, N=16; for *E. histolytica*→*E. histolytica*, N=20; for *E. moshkovskii*→*E. histolytica*, N=20 (A, B); for naïve→*E. moshkovskii*, N=20; for *E. histolytica*→*E. moshkovskii*, N=20; for *E. moshkovskii*→*E. moshkovskii*, N=20 (C, D). Asterisks indicate statistical significance with p < 0.05 by χ² test between mice infected with *E. histolytica* and *E. moshkovskii* in the primary infection.

Infection-induced species-specific immunity protects mice from weight loss

During the primary infection, mice infected with *E. moshkovskii* suffered severe symptoms. Following re-challenge with *E. moshkovskii* (homologous species) 14 days after treatment of the primary infection, mice did not show any weight loss (Figure 5A). Slight weight loss was observed, however, in mice re-challenged 35 days after treatment, but the severity of weight loss was much smaller than that observed during the primary infection (Figure 5B). The weight loss was also ameliorated in mice re-infected with *E. histolytica*, when having been given a primary infection with the homologous species (data not shown).

**Discussion**

Our results clearly demonstrate that exposure to, and subsequent drug clearance of, the parasitic amoebae *E. histolytica* and *E. moshkovskii* invokes a strong immune response that protects mice from subsequent infection with a homologous species. This protection is species specific, affording little to no protection against a heterologous species challenge. The fact that this strong species-specific immunity was shown to last at least 35 days following the treatment of the initial infection suggests that memory responses are involved.
Despite the fact that it has long been suspected that people may acquire immunity against amoebae, as older children in endemic areas are infected less frequently than younger children [18], this work constitutes the first experimental proof of this phenomenon. The molecular and cellular mechanisms responsible for the observed protection have not been addressed in this work. Mucosal IgA has been reported to be associated with protection against intestinal amoebiasis in humans, mice and baboons [7,8,19]. Indeed, monoclonal IgA specific for the E. histolytica galactose inhibitable adherence (GalNAc) lectin heavy subunit (HgL) is thought to inhibit its interaction with a host sugar moiety in colonic mucins, resulting in the failure of amoebae to settle within the intestines [20]. Furthermore, we and Guo et al. recently reported that IFN-γ derived from amoeba-specific T cells plays a protective role against E. moshkovskii (unpublished data) and E. histolytica [21], respectively, suggesting that T cells as well as antibodies specific for amoebic antigens are involved in acquired resistance to intestinal amoebic infections.

The phenomenon of species-specific immunity against parasitic pathogens has been studied in a number of parasitic species, perhaps most comprehensively with the Plasmodium species responsible for malaria [22]. For this pathogen, which exhibits both species and strain specific immunity, antigenic variation of major parasite surface antigens such as the merozoite surface protein 1 (MSP1), induces antibody-mediated immune responses that are effective only against the inducing-strain [22,23]. Such highly polymorphic strain- and species-specific antigens are thought to evolve through the actions of positive diversifying selection, so that proteins that are targeted by the host immune response rapidly accumulate polymorphisms. Here we show, for the first time, that the phenomenon of species-specific immunity also exists for Entamoeba spp. It seems probable that this is due to

Figure 4. The protection induced by primary infection lasts more than four weeks. Mice were infected with $1 \times 10^6$ trophozoites of Entamoeba histolytica (open triangle) or Entamoeba moshkovskii (open circle) and treated with metronidazole (Mz) on day 14 following induction of the primary infection. The clearance of amoeba was confirmed seven days after treatment by PCR. Mice were kept without any intervention for 28 days, and re-challenged with $1 \times 10^6$ trophozoites of E. histolytica (A, B) or E. moshkovskii (C, D) at 35 days after treatment. The number of mice used was as follows: for naïve→E. histolytica, N=16; for E. histolytica→E. histolytica, N=20; for E. moshkovskii →E. histolytica, N=26 (A, B); for naïve→E. moshkovskii, N=15; for E. histolytica→E. moshkovskii, N=20; for E. moshkovskii →E. moshkovskii, N=20 (C, D). Asterisks indicate statistical significance with $p < 0.05$ by χ² test between mice infected with E. histolytica and E. moshkovskii in the primary infection.

doi: 10.1371/journal.pone.0082025.g004

Figure 5. The change of body weight was monitored after re-challenging mice with Entamoeba moshkovskii. The naïve mice or mice exposed to primary E. moshkovskii infection were re-challenged with $1 \times 10^6$ trophozoites of E. moshkovskii at 7 or 28 days after confirming the clearance of primary infection. The studies were repeated 3 times with similar results. Asterisks indicate statistical significance with $p < 0.05$ between the groups of mice with primary and secondary infection using unpaired Student’s t-test.

doi: 10.1371/journal.pone.0082025.g005
polymorphisms in major antigen target proteins between species. If so, then such antigens may be identified by comparative genomics. Of particular interest are the GalNAc-lectin HgL proteins previously implicated in antibody-mediated protection against *E. histolytica*. Nucleotide sequence comparisons of the genes encoding this protein in *E histolytica* and *E. moshkovskii* may shed further light on this.

We found that *E. moshkovskii* is susceptible to the anti-amoeba drug metronidazole both in *vitro* and *in vivo* to the same degree as *E. histolytica*. This finding supports the use of this drug in the treatment of pathogenic *E. moshkovskii*, and may ease concerns of treatment failure following cases of misdiagnosis of *E. moshkovskii* as *E. histolytica*.

In summary, we show that exposure to a single drug cured amoebic infection confers resistance to re-challenge with the homologous, but not a heterologous species, for the first time, which species-specific acquired immunity has been demonstrated for amoebic infections. This work paves the way, therefore, for the identification of novel amoeba antigens that may become the targets of vaccines.

References

1. Bryce J, Boschi-Pinto C, Shibuya K, Black RE (2005) WHO estimates of the causes of death in children. Lancet 365: 1147-1152. doi:10.1016/S0140-6736(05)71877-8. PubMed: 15794969.
2. Petri WA Jr, Miller M, Binder JH, Levine MM, Dillingham R et al. (2008) Entamoeba infections, diarrhea, and their impact on function and development. J Clin Invest 118: 1277-1290. doi:10.1172/JCI34005. PubMed: 18382740.
3. Guerrant RL, Orià RB, Moore SR, Orià MO, Lima AA (2008) Malnutrition as an enteric infectious disease with long-term effects on colonization by pathogenic Entamoeba histolytica in amebic liver abscess: prevalence, response to therapy, and pathogenic potential. J Clin Investig 119: 893-899. doi:10.1192/clinics/119.4.899. PubMed: 1576284.
4. Biesermann J, Ali IK, Nu PA, Dinh BT, Viet TQ et al. (2003) Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. J Clin Microbiol 41: 4745-4750. doi:11.128_UCM.41.10.1945-4750.2003. PubMed: 14532214.
5. Haque R, Mondal D, Duggal P, Kabir M, Roy S et al. (2006) Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun 74: 904-909. doi:10.1128/IAI.74.2.904-909.2006. PubMed: 16428733.
6. Blessmann J, Ali IK, Nu PA, Dinh BT, Viet TQ et al. (2003) Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. J Clin Microbiol 41: 4745-4750. doi:11.128UCM.41.10.1945-4750.2003. PubMed: 14532214.
7. Petri WA Jr, Miller M, Binder JH, Levine MM, Dillingham R et al. (2008) Entamoeba infections, diarrhea, and their impact on function and development. J Clin Investig 118: 1277-1290. doi:10.1172/JCI34005. PubMed: 18382740.
8. Guerrant RL, Orià RB, Moore SR, Orià MO, Lima AA (2008) Malnutrition as an enteric infectious disease with long-term effects on colonization by pathogenic Entamoeba histolytica in amebic liver abscess: prevalence, response to therapy, and pathogenic potential. J Clin Investig 119: 893-899. doi:10.1192/clinics/119.4.899. PubMed: 1576284.
9. Biesermann J, Ali IK, Nu PA, Dinh BT, Viet TQ et al. (2003) Longitudinal study of intestinal Entamoeba histolytica infections in asymptomatic adult carriers. J Clin Microbiol 41: 4745-4750. doi:11.128UCM.41.10.1945-4750.2003. PubMed: 14532214.
10. Hamano S, Asgharpour A, Stroup SE, Wynn TA, Leiter EH et al. (2006) Resistance of C57BL/6 mice to amoebiasis is mediated by nonhemopoietic cells but requires hemopoietic IL-10 production. J Immunol 177: 1208-1213. PubMed: 16818779.
11. Diamond LS, Harlow DR, Cuninck CC (1978) A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba. Trans R Soc Trop Med Hyg 72: 431-432. doi:10.1016/S0335-9023(78)90144-X. PubMed: 212851.
12. Hamzah Z, Pettnir S, Mungthin M, Leelayoova S, Chavalitshewinkoon-Pettnir P (2006) Differential detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii by a single-round PCR assay. J Clin Microbiol 44: 3196-3200. doi:10.1128/JCM.00778-06. PubMed: 16954247.
13. Houpt ER, Glenbocki DJ, Obrig TG, Moskaluk CA, Lockhart LA et al. (2002) The mouse model of amebic colitis reveals mouse strain susceptibility to infection and exacerbation of disease by CD4 - T cells. J Immunol 169: 4496-4503. PubMed: 12370386.
14. Asgharpour A, Gilchrist C, Baba D, Hamano S, Houpt E (2005) Resistance to intestinal Entamoeba histolytica infection is conferred by innate immunity and Gr-1 + cells. Infect Immun 73: 4522-4529. doi:10.1128/IAI.73.8.4522-4529.2005. PubMed: 1680963.
15. Hamano S, Becker S, Asgharpour A, Osayo VP, Stroup SE et al. (2008) Gender and genetic control of resistance to intestinal amebiasis in inbred mice. Genes Immun 9: 452-461. doi:10.1038/genes.2008.37. PubMed: 18480828.
16. Haque R, Mondal D, Duggal P, Kabir M, Roy S et al. (2006) Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun 74: 904-909. doi:10.1128/IAI.74.2.904-909.2006. PubMed: 16428733.
17. Abd Alia MD, Wolf R, White GL, Kosanke SD, Cary D et al. (2012) Efficacy of a Gal-lectin subunit vaccine against experimental Entamoeba histolytica infection and collits in baboons (Papio sp.). Vaccine 30: 3068-3075. doi:10.1016/j.vaccine.2012.02.066. PubMed: 22406547.
18. Haque R, Mondal D, Duggal P, Kabir M, Roy S et al. (2006) Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun 74: 904-909. doi:10.1128/IAI.74.2.904-909.2006. PubMed: 16428733.
19. Inoue M, Tang J, Miyakoda M, Kaneko O, Yui K et al. (2012) The pathogenicity in CBA mice owes to intestinal IL-4 production and causes diarrhea and colitis in mice. J Infect Dis 206: 744-751. doi:10.1093/infdis/jis341. PubMed: 22723640.
20. Hamano S, Asgharpour A, Stroup SE, Wynn TA, Leiter EH et al. (2006) Resistance of C57BL6 mice to amoebiasis is mediated by nonhemopoietic cells but requires hemopoietic IL-10 production. J Immunol 177: 1208-1213. PubMed: 16818779.
21. Martineili A, Cheesman S, Hunt P, Cullenet R, Raza A et al. (2005) A genetic approach to the de novo identification of targets of strain-specific immunity in malaria parasites. Proc Natl Acad Sci U S A 102: 814-819. doi:10.1073/pnas.0450971102. PubMed: 15640359.

Acknowledgements

We thank Fumie Har, Masako Hayashida and Megumi Hamasaki for animal husbandry; Tomoko Takaya, Hiromi Oda and Rumiko Kosugi for administrative support; Richard Cullenet for scientific editing; members of Institute of Tropical Medicine, Nagasaki University and Department of Parasitology, Graduate School of Medicine, Gunma University for technical assistance and precious comments.

Author Contributions

Conceived and designed the experiments: CS SH. Performed the experiments: CS TI KS MH TT SK. Analyzed the data: CS RH HH. Contributed reagents/materials/analysis tools: CS SK SH. Wrote the manuscript: CS RC SH.